awmsg logo



darunavir (Prezista®)


Reference No. 1383

Publication date:
31/07/2013


Appraisal information

darunavir (Prezista®) 100 mg/ml oral suspension


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: 10/04/2013
AWMSG meeting date: 08/05/2013
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1213
Ministerial ratification: 29/07/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Darunavir (Prezista®) 100 mg/ml oral suspension, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales, in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients, as well as antiretroviral therapy-experienced paediatric patients from the age of 3 years and at least 15 kg body weight.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download